cbdMD announced that it has received validation of its Novel Food application from the United Kingdom’s Food Standards Agency (FSA) for its natural plant-based CBD formulation and is now the first American CBD brand to achieve this significant milestone. It also anticipates validation of its application to the European Food Safety Authority in the coming weeks.

Over 800 companies submitted applications and only those that submitted dossiers based on safety data with their own ingredients have been validated. cbdMD will now be allowed to sell its proprietary and validated tinctures, gummies, and capsules across the UK. The company anticipates its ability to fulfill orders from its UK distributors and e-commerce platforms in the coming weeks. The grant of validation was based on the company’s extensive toxicological data, which contained all the requisite evidence to substantiate the safe consumption of the company’s products which contain cbdMD’s proprietary blend of cannabinoids. Competitors who submitted applications using shared data are not expected to receive validation. cbdMD’s safety data will be used as the basis for additional research and regulatory studies which the company intends to use to validate the safety and efficacy of its products in other international markets and the US

 “This FSA validation certifies what we’ve known all along, our products are safe. We want to thank the FSA for validating this fact, and we strongly urge the USFDA to do the same. Our customers trust and appreciate that our products are formulated with natural ingredients, not synthetic copies, and without additives. In a time when the world needs products that complement everyday health and wellness, our natural products matter and resonate with consumers worldwide,” said Martin A. Sumichrast, Chairman & co-CEO of cbdMD.